Abstract: ObjectiveTo study the protective effects of valsartan combined with/without ulinastatin on primary hepatic carcinoma with liver cirrhosis and portal hypertension in patients with hepatic ischemia-reperfusion injury. MethodsThirty patients with hepatic carcinoma scheduled for hepatectomy were divided into three groups randomly: control group, ulinastatin group, valsartan and ulinastatin combined group. Ulinastatin group by 10 000 u / kg after induction of anesthesia before skin incision add 5% glucose intravenous drip of saline 100 ml. Combined group was given valsartan orally 80 mg once daily for a week, intraoperative with ulinastatin group. Control group, 5% glucose intravenous infusion of saline 100ml. Venous blood samples were used to measure the concentration of TXB2 and 6-keto-PGF1α, before, end and opening 60 min of the hilar blocking separately in three groups. Preoperative, postoperative 1 day, 3 days and 5 days venous blood samples for alanine aminotransferase, aspartate aminotransferase and total bilirubin measurement. ResultsAll 30 cases had been resected successfully, three groups of patients with TXB2, 6-keto-PGF1α, alanine aminotransferase, aspartate aminotransferase and total bilirubin in plasma increased (P<0.05), ulinastatin group and combined group rate of increase were lower than the control group (P<0.05), but the protective effect of combined group and alone ulinastatin group had no significant difference (P>0.05). ConclusionUlinastatin group had obvious protective effect on the patients of hilar primary hepatic carcinoma with liver cirrhosis and portal hypertension, but the effect of Ulinastatin combining with valsartan, needs to be explored further.